Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients

뉴스 본문을 불러오고 있어요.

Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients | 웨이프 WAPE

Polyrizon Says It Completed Contracting With All Five U.S. Clinical Sites For First-In-Human Study Of NASARIX Allergy Blocker, Planned To Enroll Up To 120 Patients

기사 요약

관련 종목

댓글 —